Skip to main content

Table 1 Baseline characteristics of the study population

From: “Sarcopenia and intramuscular fat deposition are associated with poor survival in Indonesian patients with hepatocellular carcinoma: a retrospective study”

CharacteristicN = 100
Age, mean ± SD55.03 ± 11.20
Gender, male, %74
Body mass index (kg/m2), median (IQR)18.83 (17.78–23.11)
  < 18.5 (underweight), N (%)31
 18.5–22.9 (normal weight), N (%)44
 23.0–24.9 (overweight), N (%)6
  ≥ 25.0 (obesity), N (%)19
Viral status, %
 HBV/HCV/HBV + HCV/none58/8/0/34
Child–Pugh classification, %
 A/B/C60/32/8
BCLC stage, %
 A/B/C/D7/25/59/9
ECOG PS, %
 0/1/2/332/41/22/5
LCSGJ TNM stage, %
 1/2/3/40/21/32/47
AJCC TNM stage 8th edition, %
 1/2/3/420/5/32/43
JIS score, %
 1/2/3/4/518/23/31/23/5
Treatment, %
 Curative (liver transplant, resection, PEIT, RFA)0
 Palliative (TACE, sorafenib)65
 Supportive (end-stage life support)35
Alcohol consumption, %
 Yes/no8/72
Clinical signs and symptoms, %
 Malaise, nausea, vomiting/hematemesis or melena76/11
 Abdominal pain/weight loss68/80
 Jaundice/ascites25/32
 Hepatomegaly/splenomegaly92/30
Tumour diameter, mean ± SD (cm)12.05 ± 4.97
Type of tumour, %
 Nodular/diffuse65/35
 Single/multiple30/70
  1. SD Standard deviation, BCLC Barcelona Clinic Liver Cancer, ECOG PS Eastern Cooperative Oncology Group Performance Status, TNM Tumour-node-metastasis, LCSGJ Liver Cancer Study Group of Japan, TNM Classification system, AJCC American Joint Committee of on Cancer, JIS Japan Integrated Staging, PEIT Percutaneous ethanol injection therapy, RFA Radiofrequency ablation, TACE Transarterial chemoembolisation